Aurobindo Pharma has rallied 6% to Rs 525 after reporting over four-fold jumped in consolidated net profit at Rs 417 crore for the third quarter ended December 31, 2013 (Q3) on back of strong operational income. The pharmaceutical company had profit of Rs 92 crore in the same quarter previous fiscal.
The company’s total income rose 36% year-on-year (yoy) at Rs 2,144 crore as compared with Rs 1,576 crore in the corresponding quarter previous year while the expenditure went up 14.64% to Rs 1,573 crore from Rs 1,372 crore in the year ago period.
The grow was mainly driven by the US formulations, which grew by 81.4% yoy, along with the ARV and EU formulation sales, which posted a yoy growth of 25.4% and 36.6% yoy respectively.
The stock opened at Rs 530 and touched a record high of Rs 540 on the NSE. A combined 3.4 million shares changed hands on the counter so far on the BSE and NSE.
The company’s total income rose 36% year-on-year (yoy) at Rs 2,144 crore as compared with Rs 1,576 crore in the corresponding quarter previous year while the expenditure went up 14.64% to Rs 1,573 crore from Rs 1,372 crore in the year ago period.
The grow was mainly driven by the US formulations, which grew by 81.4% yoy, along with the ARV and EU formulation sales, which posted a yoy growth of 25.4% and 36.6% yoy respectively.
The stock opened at Rs 530 and touched a record high of Rs 540 on the NSE. A combined 3.4 million shares changed hands on the counter so far on the BSE and NSE.
